AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Insidehealthpolicy

Published November 13, 2026 · Updated November 14, 2026

AMA: Cautious Approach Needed To Psychedelic Human Trials | InsideHealthPolicy.com

Read the full story at Insidehealthpolicy

The American Medical Association is urging FDA to adopt a cautious approach to studying ibogaine and other psychedelic drugs for potential mental.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics